CN118556083A - 具有改善的治疗指数的靶向cd3的t细胞衔接器 - Google Patents

具有改善的治疗指数的靶向cd3的t细胞衔接器 Download PDF

Info

Publication number
CN118556083A
CN118556083A CN202280082274.2A CN202280082274A CN118556083A CN 118556083 A CN118556083 A CN 118556083A CN 202280082274 A CN202280082274 A CN 202280082274A CN 118556083 A CN118556083 A CN 118556083A
Authority
CN
China
Prior art keywords
seq
antibody
amino acid
acid sequence
taa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280082274.2A
Other languages
English (en)
Chinese (zh)
Inventor
方磊
杨柳
高珊
巩文词
杨园园
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lepu Biotechnology Co ltd
Original Assignee
Lepu Chuangyi Biotechnology Shanghai Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lepu Chuangyi Biotechnology Shanghai Co ltd filed Critical Lepu Chuangyi Biotechnology Shanghai Co ltd
Publication of CN118556083A publication Critical patent/CN118556083A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202280082274.2A 2021-10-12 2022-10-12 具有改善的治疗指数的靶向cd3的t细胞衔接器 Pending CN118556083A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/123374 2021-10-12
CN2021123374 2021-10-12
CNPCT/CN2022/104995 2022-07-11
CN2022104995 2022-07-11
PCT/CN2022/124961 WO2023061417A1 (en) 2021-10-12 2022-10-12 Cd3-targeting t-cell engagers with improved therapeutic index

Publications (1)

Publication Number Publication Date
CN118556083A true CN118556083A (zh) 2024-08-27

Family

ID=85987305

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280082274.2A Pending CN118556083A (zh) 2021-10-12 2022-10-12 具有改善的治疗指数的靶向cd3的t细胞衔接器

Country Status (5)

Country Link
US (1) US20240417469A1 (cg-RX-API-DMAC10.html)
EP (1) EP4415825A4 (cg-RX-API-DMAC10.html)
JP (1) JP2024540863A (cg-RX-API-DMAC10.html)
CN (1) CN118556083A (cg-RX-API-DMAC10.html)
WO (1) WO2023061417A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN122070305A (zh) * 2023-09-21 2026-05-19 艾科联生物科技(上海)有限公司 多特异性抗体及其用途
WO2025103425A1 (en) * 2023-11-15 2025-05-22 Concept To Medicine Biotech Co., Ltd. Multispecific antibodies and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY200973A (en) * 2017-04-11 2024-01-26 Inhibrx Inc Multispecific Polypeptide Constructs Having Constrained Cd3 Binding And Methods Of Using The Same
TW202010757A (zh) * 2018-04-11 2020-03-16 美商英伊布里克斯公司 具有經受限cd3結合的多重特異性多肽構築體以及相關方法及用途
WO2020023553A1 (en) * 2018-07-24 2020-01-30 Inhibrx, Inc. Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same
JP2022501325A (ja) * 2018-09-28 2022-01-06 中外製薬株式会社 改変された抗体可変領域を含む抗原結合分子
CN113166261A (zh) * 2018-10-11 2021-07-23 印希比股份有限公司 B7h3单域抗体及其治疗性组合物
US12590169B2 (en) * 2018-10-11 2026-03-31 Inhibrx Biosciences, Inc. 5T4 single domain antibodies and therapeutic compositions thereof
CN110669137B (zh) * 2019-10-24 2021-07-16 高新 一种多特异性抗体及其制备方法和用途
EP4110820A4 (en) * 2020-02-25 2024-03-27 Gensun Biopharma Inc. Trispecific t cell engagers

Also Published As

Publication number Publication date
US20240417469A1 (en) 2024-12-19
JP2024540863A (ja) 2024-11-06
WO2023061417A1 (en) 2023-04-20
EP4415825A1 (en) 2024-08-21
EP4415825A4 (en) 2026-01-07

Similar Documents

Publication Publication Date Title
KR102224556B1 (ko) Ig 및 itim 도메인을 갖는 t 세포 면역 수용체 (tigit)에 대한 항체 및 이것의 사용
KR102536145B1 (ko) 항-pd-1 항체 및 이의 용도
JPWO2018147245A1 (ja) 抗gprc5d抗体及び該抗体を含む分子
CN118510803A (zh) 对人和食蟹猴蛋白具有交叉反应性的抗cd3抗体
CN118994403B (zh) 抗磷脂酰肌醇蛋白聚糖3抗体
KR20240067052A (ko) 항-ccr8 항체
JP2023547530A (ja) 抗tigit抗体およびその使用
WO2023056969A1 (en) Bispecific antibodies specifically binding to cd47 and cd20, and uses thereof
US20240383983A1 (en) Anti-B7-H4/Anti-4-1BB Bispecific Antibodies And Use Thereof
KR20220024211A (ko) 항-cd47 항체 및 그것의 사용
JP2017512772A (ja) Lg1〜3に特異的な抗ラミニン4抗体
WO2023061417A1 (en) Cd3-targeting t-cell engagers with improved therapeutic index
JP2025541340A (ja) Cub domain-containing protein 1(cdcp1)に対する抗体およびその使用
WO2023056970A1 (en) Bispecific antibodies specifically binding to cd47 and her2, and uses thereof
TW202600594A (zh) 結合構築體(一)
WO2021204281A1 (en) Anti-cd47 antibody and uses thereof
HK40108102A (en) Cd3-targeting t-cell engagers with improved therapeutic index
TWI806870B (zh) 抗pd-1抗體及其用途
HK40110049A (en) Anti-cd3 antibodies with cross-reactivity to human and cynomolgus proteins
WO2025061132A1 (en) Anti-dll3 antibodies and uses thereof
US20260078196A1 (en) Multispecific constructs and uses thereof
US20250230234A1 (en) Anti-gprc5d antibodies and compositions
HK40113267A (en) Anti-glypican 3 antibodies
HK40067877A (en) Antibodies to cd3 and bcma, and bispecific binding proteins made therefrom
HK40016537A (en) Anti-pd-1 antibodies and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40108102

Country of ref document: HK

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20250612

Address after: 201112 Shanghai City Minhang District Pujiang Lianheng Road No. 651 Building 4 2nd Floor

Applicant after: Lepu Biotechnology Co.,Ltd.

Country or region after: China

Address before: 201203 Shanghai Pudong New Area Zhangheng Road 1077, Room B207 Dade Chuangtong

Applicant before: Lepu Chuangyi Biotechnology (Shanghai) Co.,Ltd.

Country or region before: China